MarketCapExport financials
C4 Therapeutics (CCCC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
C4 Therapeutics Income Statement 2025-2011 | CCCC
Brief overview of income trends at C4 Therapeutics
The comparison covers a five-year financial horizon. The revenue attributed to C4 Therapeutics moved from 33.2 million dollars to 35.9 million dollars between the two endpoints. The five-year change reached +8.3%, while CAGR stood at 1.6%. The business did not achieve meaningful top-line expansion.
EBITDA changed from −58.8 million dollars to −113 million dollars (−92.5%). The operating result developed less favorably than sales. Comparing the endpoints gives EBITDA margins of −177.2% and −315.1%. The margin contraction indicates weaker operating efficiency.
Across the five years, the net result shifted from −$66.3 million to −$105 million. The period ended with a larger loss than it began with.
Market capitalization changed from $1.5 billion to $234 million (−84.1%). Market expectations deteriorated over the period.
Overall conclusion
The current trajectory does not yet confirm a sustainable recovery. The overall view is constrained by lower net income, a declining EBITDA margin and limited revenue growth. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement C4 Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
234 M | 182 M | 438 M | 300 M | 1.48 B | 1.47 B | - | - | - | - | - | - | - | - | - |
Shares |
82.9 M | 69.4 M | 49.6 M | 48.9 M | 46 M | 40.8 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
2.82 | 2.63 | 8.83 | 6.13 | 32.2 | 33.1 | - | - | - | - | - | - | - | - | - |
Net Income |
-105 M | -105 M | -132 M | -128 M | -83.9 M | -66.3 M | -34.1 M | -15.7 M | - | - | - | - | - | - | - |
Revenue |
35.9 M | 35.6 M | 20.8 M | 31.1 M | 45.8 M | 33.2 M | 21.4 M | 19.4 M | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | 33.2 M | - | - | - | - | - | - | - | - | - |
Operating Income |
-115 M | -120 M | -139 M | -130 M | -82.1 M | -60.4 M | -35.5 M | - | - | - | - | - | - | - | - |
EBITDA |
-113 M | -118 M | -137 M | -128 M | -80.6 M | -58.8 M | -33.9 M | -15.1 M | - | - | - | - | - | - | - |
Operating Expenses |
151 M | 155 M | 160 M | 161 M | 128 M | 93.6 M | 56.8 M | 35.8 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
36.2 M | 42.1 M | 42.1 M | 42.8 M | 33.3 M | 15.2 M | 8.77 M | 7.16 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement C4 Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
71 M | 126 M | - | 72.6 M | 71 M | 70.8 M | 70.6 M | 69.6 M | 68.8 M | 68.4 M | 60.5 M | 49.2 M | 49.1 M | 49 M | 49 M | 48.9 M | 48.8 M | 48.7 M | 48.7 M | 48.5 M | 43.9 M | 43.1 M | 43.1 M | 1.54 M | 1.48 M | 1.46 M | 1.43 M | 1.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-26.3 M | -25.1 M | - | -32.2 M | -26 M | -26.3 M | - | -24.7 M | -17.7 M | -28.4 M | - | -27 M | -35.9 M | -34.8 M | - | -32 M | -27.4 M | -31.6 M | - | -24.7 M | -22.6 M | -21 M | - | -21.8 M | -10.8 M | -11.9 M | - | -10.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
6.46 M | 6.15 M | - | 11.2 M | 6.46 M | 7.24 M | - | 15.4 M | 12 M | 3.04 M | - | 11.1 M | 2.66 M | 3.76 M | - | 6.75 M | 13.8 M | 7.65 M | - | 8.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-28.5 M | -27.8 M | - | -34.4 M | -28.5 M | -29.2 M | - | -28.2 M | -21.4 M | -32.2 M | - | -27.8 M | -37.6 M | -36.2 M | - | -32.5 M | -27.4 M | -31.4 M | - | -24.3 M | -22.1 M | -20.5 M | - | -18.3 M | -10.9 M | -12.3 M | - | -10 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 43 K | - | - | - | -1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-28.1 M | -27.4 M | - | -34 M | -28.1 M | -28.7 M | - | -27.9 M | -21.1 M | -31.8 M | - | -27.4 M | -37.1 M | -35.7 M | - | -32.1 M | -26.9 M | -31.1 M | - | -23.9 M | -21.7 M | -20.1 M | - | -17.9 M | -10.4 M | -11.9 M | - | -8.83 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
35 M | 33.9 M | - | 45.6 M | 35 M | 36.4 M | - | 43.6 M | 33.4 M | 35.3 M | - | 38.9 M | 40.2 M | 40 M | - | 39.2 M | 41.2 M | 39 M | - | 32.8 M | 31.9 M | 27.9 M | - | 26.8 M | 20.5 M | 19.2 M | - | 15.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
8.77 M | 9.33 M | - | 8.92 M | 8.77 M | 9.33 M | - | 11.8 M | 9.7 M | 10.3 M | - | 10.5 M | 10.3 M | 10.9 M | - | 9.58 M | 9.9 M | 12.8 M | - | 8.45 M | 8.61 M | 7.41 M | - | 2.86 M | 2.77 M | 2.84 M | - | 2.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company C4 Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
France
Israel
Australia
Irlanda